Inactive Instrument

Alexion Pharmaceuticals, Inc.

ALXN

US0153511094

Alexion Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2020

January 12, 2021 at 12:15 pm

Alexion Pharmaceuticals, Inc. revised earnings guidance for the year 2020. The company expects to exceed the high end of the Company's 2020 revenue guidance of $5.9 billion to $5.95 billion that was previously provided by the Company in connection with its third quarter 2020 financial results.

Latest news about Alexion Pharmaceuticals, Inc.

Alexion Pharmaceuticals, Inc.'s VOYDEYA Receives Approval in US Add-On Therapy to Ravulizumab or Eculizumab for Treatment of Extravascular Hemolysis in Adults with the Rare Disease PNH	04-01	CI
Alexion Announces Long-Term Alpha Phase III Trial Data Shows Danicopan as Add-On to Standard of Care C5 Inhibitor Therapy ULTOMIRIS	12-11	CI
Alexion Pharmaceuticals, Inc. completed the acquisition of Assets of early-stage rare disease gene therapy portfolio of Pfizer Inc..	18/09/23	CI
Verge Genomics Announces Artificial Intelligence-Enabled Drug Discovery Collaboration with Alexion for Rare Neurodegenerative and Neuromuscular Diseases	08/09/23	CI
Alexion Pharmaceuticals, Inc. entered a definitive purchase agreement to acquire Assets of early-stage rare disease gene therapy portfolio of Pfizer Inc. for $1 billion.	27/07/23	CI
JCR Pharmaceuticals Co., Ltd. Announces Research Collaboration, Option and License Agreement with Alexion to Develop a Therapy Using J-Brain CargoR for Neurodegenerative Disease	30/03/23	CI
Alexion Pharmaceuticals, Inc. completed the acquisition of LogicBio Therapeutics, Inc. from a group of shareholders.	14/11/22	CI
Alexion Pharmaceuticals, Inc. Aims to Advance Nmosd Treatment Landscape with Exceptional Ultomiris® (Ravulizumab-Cwvz) Efficacy Data At Ectrims 2022	12/10/22	CI
Alexion Pharmaceuticals, Inc. entered into a definitive agreement to acquire LogicBio Therapeutics, Inc. from a group of shareholders for $68.2 million.	02/10/22	CI
Alexion Pharmaceuticals, Inc Announces Danicopan Add-On to Ultomiris (Ravulizumab-Cwvz) or Soliris Met Primary Endpoint in Alpha Phase III Trial for Patients with Paroxysmal Nocturnal Hemoglobinuria Who Experience Clinically Significant Extravascular Hemolysis	16/09/22	CI
Alexion, Astrazeneca's Rare Disease Group and Neurimmune Closes Deal for Commercializing Ni006	01/03/22	CI
Alexion Enters into an Exclusive Global Collaboration and Licence Agreement with Neurimmune AG	07/01/22	CI
Alexion Pharmaceuticals, Inc. completed the acquisition of remaining majority stake in Caelum Biosciences, Inc. from Fortress Biotech, Inc. and others.	04/10/21	CI
AstraZeneca's Alexion to Advance and Accelerate Ongoing Phase III Clinical Development of Cael-CAEL, a Potential Medicine for AL Amyloidosis	29/09/21	CI
Alexion Pharmaceuticals, Inc. agreed to acquire remaining majority stake in Caelum Biosciences, Inc. from Fortress Biotech, Inc. and others for $500 million.	28/09/21	CI
AstraZeneca : to Mandate COVID-19 Shots for US Staff	31/08/21	MT
AstraZeneca : Rare Disease Drug Improves Copper Mobilization in Late-Stage Study	26/08/21	MT
FTSE : Consumer staples, financials lift FTSE 100 after worst week since February	20/08/21	RE
AstraZeneca : Unit Alexion Discontinues Late-Stage Trial of ALS Drug Candidate Due to Lack of Efficacy	20/08/21	MT
FTSE 100 Falls as Growth Fears Persist; More Volatility Possible	20/08/21	DJ
AstraZeneca : antibody therapy prevents COVID-19, study shows	20/08/21	RE
Alexion Discontinues CHAMPION-ALS	20/08/21	CI
AstraZeneca : Alexion to Discontinue Ultomiris Phase 3 ALS Trial	20/08/21	DJ
AstraZeneca : Exclusive - AstraZeneca exploring options for COVID-19 vaccine business - executive	29/07/21	RE
London Indexes Boosted by Positive Welcome to Most Earnings	29/07/21	DJ

Chart Alexion Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on discovering, development and commercialization of medicines. The Company's marketed products include ULTOMIRIS, SOLIRIS (eculizumab), STRENSIQ (asfotase alfa), KANUMA (sebelipase alfa) and ANDEXXA (coagulation Factor Xa - [recombinant] inactivated-zhzo). Its ULTOMIRIS product is a long-acting C5 inhibitor, that works by inhibiting the C5 protein in the terminal complement cascade. Its SOLIRIS product is a humanized monoclonal antibody that blocks terminal activity at the doses prescribed. Its Strensiq product is a targeted enzyme replacement therapy for patients with Hypophosphatasia (HPP). Its Kanuma product is a recombinant form of the human lysosomal acid lipase (LAL) enzyme. Its ANDEXXA product is a reversal agent for patients treated with rivaroxaban or apixaban.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+55.35%	815B
NOVO NORDISK A/S	+32.07%	597B
JOHNSON & JOHNSON	-0.10%	377B
MERCK & CO., INC.	+15.47%	319B
ABBVIE INC.	+13.10%	310B
ASTRAZENECA PLC	+16.11%	247B
NOVARTIS AG	+13.97%	228B
AMGEN INC.	+16.54%	180B
PFIZER, INC.	+4.31%	170B

Other Pharmaceuticals